Le Fur stays mum on merger

February 2007
ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p13
Trade Publication
The article emphasizes the decision of Sanofi-Aventis chief executive officer (CEO) Gérard Le Fur to keep quiet on the issue about their merger with Bristol-Myers Squib. During the full-year results conference of Sanofi-Aventis, Le Fur declined to answer any questions related to the merger. He simply said that they never comment on rumours. Le Fur was more forthcoming on other aspects of the group's development strategy, revealing that Japan was the priority for external growth.


Related Articles

  • Le Fur stays mum on merger.  // ICIS Chemical Business Americas;2/19/2007, Vol. 271 Issue 7, p13 

    The article reports that Gérard Le Fur, chief executive officer (CEO) of Sanofi-Aventis, refused to answer any questions concerning a possible merger of his group with Bristol-Myers Squib. It mentions that Le Fur revealed that Japan was the company's priority for external growth. Its...

  • Takeover news.  // Dow Theory Forecasts;2/5/2007, Vol. 63 Issue 6, p7 

    The article offers news briefs regarding takeover of companies. Bristol-Myers Squibb rallied on takeover speculation, with French business publication Sanofi-Aventis considering to make a bid for the company. Citigroup agreed to buy London-Based Egg Banking PLC from British insurer Prudential...

  • A merger too far? Wadman, Meredith // Nature;3/1/2007, Vol. 446 Issue 7131, p15 

    The article reports on the possible merger between Bristol-Myers Squibb Co. and Sanofi-Aventis SA in California. Although talks between the two had been ineffective, it could yet be restored if their patent dispute could be settled. However, experts believe that Bristol-Myers still have much to...

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Dec2008, Vol. 7 Issue 12, p9 

    The article offers world news briefs related to pharmaceutical industry. Sanofi-Aventis has announced positive data from the Athena trial which found that dronedarone reduced the incidence and total duration of hospital stays among patients with atrial fibrillation. Morever, The Medicines Co....

  • CORPORATE.  // MondayMorning;1/17/2011, Vol. 19 Issue 2, p2 

    The article provides U.S. pharmaceutical industry news briefs. Community Health Systems Inc. of Franklin, Tennessee has bidded for Tenet Healthcare Corp. of Dallas, Texas for 3.3 billion dollars. Bristol-Myers Squibb CO. of New York and Pharmasset Inc. of Princeton New Jersey said they will...

  • Sanofi-Aventis/Bristol-Myers Squibb: eyeing pole position.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p34 

    The article reports on the rumors circulating that France-based Sanofi-Aventis SA and U.S. rival Bristol-Myers Squibb Co. (BMS) are considering a merger which would establish the largest pharmaceutical company in the world, with combines 2006 drug revenues of around $49.1 billion. Sanofi-Aventis...

  • Antibodies' long revenue stream spurs pharma acquisitions. Mitchell, Peter // Nature Biotechnology;Nov2007, Vol. 25 Issue 11, p1194 

    The article reports on the implication of the mergers and acquisition craze in the pharmaceutical industry in the U.S. Few of them include Bristol-Myers Squibb Co.'s purchase of Adnexus Therapeutics, Wyeth Inc. of Haptogen Ltd. and Sanofi Aventis SA of ImClone Systems Inc. Such moves imply that...

  • Plavix Granted Additional Exclusivity.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p50 

    The article reports on the announcement of Bristol-Myers Squibb co. and Sanofi-Aventis SA that the Food and Drug Administration (FDA) has granted them additional six-month period of exclusivity in marketing Plavix (clopidogrel bisulfate) for adult patients with acute coronary syndrome in the U.S.

  • BMS After ImClone; Offers $60 per Share for Erbitux Partner. Boggs, Jennifer // BioWorld Today;8/1/2008, Vol. 19 Issue 149, p1 

    The article reports on the bid for ImClone Systems Inc. by Bristol-Myers Squibb Co. (BMS). As part of its expansion strategy, BMS is offering to buy all the remaining shares of ImClone for around $4.5 billion or $60 per share. It is noted that BMS will have full rights of Erbitux, an endothelial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics